Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ORMP's Cash to Debt is ranked higher than
84% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ORMP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ORMP' s 10-Year Cash to Debt Range
Min: 1.06  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
ORMP's Interest Coverage is ranked higher than
69% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ORMP: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ORMP' s 10-Year Interest Coverage Range
Min: 128.16  Med: 10000.00 Max: 9999.99
Current: No Debt
128.16
9999.99
F-Score: 3
Z-Score: 54.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -30.62
ORMP's ROE (%) is ranked lower than
51% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. ORMP: -30.62 )
Ranked among companies with meaningful ROE (%) only.
ORMP' s 10-Year ROE (%) Range
Min: -8090  Med: -82.18 Max: -39.39
Current: -30.62
-8090
-39.39
ROA (%) -29.59
ORMP's ROA (%) is ranked lower than
53% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ORMP: -29.59 )
Ranked among companies with meaningful ROA (%) only.
ORMP' s 10-Year ROA (%) Range
Min: -468.93  Med: -69.51 Max: -37.4
Current: -29.59
-468.93
-37.4
ROC (Joel Greenblatt) (%) -218.34
ORMP's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ORMP: -218.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ORMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -313200  Med: -2483.18 Max: 5234
Current: -218.34
-313200
5234
EBITDA Growth (3Y)(%) 31.70
ORMP's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ORMP: 31.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ORMP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.8  Med: -0.50 Max: 57
Current: 31.7
-10.8
57
EPS Growth (3Y)(%) 28.80
ORMP's EPS Growth (3Y)(%) is ranked higher than
84% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ORMP: 28.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ORMP' s 10-Year EPS Growth (3Y)(%) Range
Min: -24.7  Med: -0.60 Max: 183
Current: 28.8
-24.7
183
» ORMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ORMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.35
ORMP's P/B is ranked higher than
63% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ORMP: 3.35 )
Ranked among companies with meaningful P/B only.
ORMP' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 28.2
Current: 3.35
0
28.2
Current Ratio 22.62
ORMP's Current Ratio is ranked higher than
92% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ORMP: 22.62 )
Ranked among companies with meaningful Current Ratio only.
ORMP' s 10-Year Current Ratio Range
Min: 0.13  Med: 6.99 Max: 67.68
Current: 22.62
0.13
67.68
Quick Ratio 22.62
ORMP's Quick Ratio is ranked higher than
93% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ORMP: 22.62 )
Ranked among companies with meaningful Quick Ratio only.
ORMP' s 10-Year Quick Ratio Range
Min: 0.13  Med: 6.99 Max: 67.68
Current: 22.62
0.13
67.68

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.35
ORMP's Price/Tangible Book is ranked higher than
69% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ORMP: 3.35 )
Ranked among companies with meaningful Price/Tangible Book only.
ORMP' s 10-Year Price/Tangible Book Range
Min: 2.19  Med: 8.46 Max: 75.6
Current: 3.35
2.19
75.6
Earnings Yield (Greenblatt) (%) -12.30
ORMP's Earnings Yield (Greenblatt) (%) is ranked lower than
69% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ORMP: -12.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ORMP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -666.7  Med: 0.00 Max: 9.3
Current: -12.3
-666.7
9.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ORMP.Switzerland, OJU1.Germany,
Oramed Pharmaceuticals Inc was incorporated on April 12, 2002, under the laws of the state of Nevada. It is a pharmaceutical company engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. The Company is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD0801) currently in Phase 2 clinical trials. The Company plans to continue to conduct clinical trials to show the effectiveness of its technology. It filed two additional provisional patents for a suppository application to its technology portfolio. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.
» More Articles for ORMP

Headlines

Articles On GuruFocus.com
Coverage Initiation Report Focuses on Oramed Pharmaceuticals Nov 11 2014 

More From Other Websites
Cell MedX Aiming to Change Diabetes Care Forever Jul 21 2015
3 Stocks Under $10 to Trade for Breakouts Jul 14 2015
Oramed's Quick Road to Market as Global Leader of Oral Insulin Capsule Jul 08 2015
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events Jul 07 2015
Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing... Jul 07 2015
Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing... Jul 07 2015
Oramed Pharmaceuticals (ORMP) in Focus: Stock Up 19.2% - Tale of the Tape Jul 06 2015
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure Jul 02 2015
3 Stocks Under $10 Triggering Breakout Trades Jul 02 2015
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Jul 01 2015
Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study Jun 30 2015
Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study Jun 30 2015
Oramed Submits Protocol to U.S. FDA for its Phase IIb Oral Insulin Study Jun 30 2015
Oramed Granted Patent in Russia for Oral Administration of GLP-1 Jun 18 2015
Oramed Granted Patent in Russia for Oral Administration of GLP-1 Jun 16 2015
Oramed Announces Closing of $5.36 Million Registered Direct Offering Jun 11 2015
Oramed Announces Closing of $5.36 Million Registered Direct Offering Jun 11 2015
Oramed to Raise $5.36 Million in Registered Direct Offering Jun 05 2015
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 05 2015
Oramed to Raise $5.36 Million in Registered Direct Offering Jun 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK